Mesenchymal stem cell therapies - Stempeutics

Drug Profile

Mesenchymal stem cell therapies - Stempeutics

Alternative Names: ex-vivo cultured adult human mesenchymal stem cells - Stempeutics; ex vivo cultured adult allogenic mesenchymal stem cells - Stempeutics; ex-vivo cultured adult bone marrow derived allogeneic mesenchymal stem cells - Stempeutics; Stempeucel; stempeucel AMI™; stempeucel CLI™; stempeucel COPD™; stempeucel CS™; stempeucel DCM™; stempeucel DM™; stempeucel LC™; stempeucel OA™

Latest Information Update: 20 Apr 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Stempeutics
  • Class Antineoplastics; Stem cell therapies
  • Mechanism of Action Osteogenesis stimulants; Tissue replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Thromboangiitis obliterans
  • New Molecular Entity No
  • Available For Licensing Yes - Osteoarthritis; Peripheral ischaemia

Highest Development Phases

  • Registered Peripheral ischaemia
  • Phase II Osteoarthritis
  • No development reported Chronic obstructive pulmonary disease; Dilated cardiomyopathy; Liver cirrhosis; Myocardial infarction; Stroke; Type 2 diabetes mellitus

Most Recent Events

  • 05 Apr 2017 Stempeutics withdrew a phase II trial prior to enrolment as DCGI directed to conduct PMS study for Peripheral ischemia (In adults) in India (NCT03056742)
  • 21 Feb 2017 Stempeutics plans a phase II trial for Peripheral ischemia in India (NCT03056742)
  • 30 May 2016 Registered for Peripheral ischaemia in India (IM)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top